GLP-1 medicines like Wegovy, Ozempic, Zepbound, and Mounjaro are not started at their full dose. Every FDA label builds in a multi-week escalation ladder, and the reason is tolerability: raising the dose too fast is the main driver of nausea, vomiting, and other gastrointestinal side effects. This tool turns those label ladders into a dated calendar so you can plan refills, travel, and dose changes around a schedule your prescriber sets.
What the labels actually require
Semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) both call for at least four weeks at each dose before moving up. Wegovy climbs 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg, reaching maintenance at 16 weeks. Tirzepatide climbs in 2.5 mg increments to a maximum of 15 mg. The low first dose — 0.25 mg or 2.5 mg — is an initiation dose to let your body adjust; it is not expected to drive weight loss on its own. Some telehealth services advertise faster ramps, but the labels do not support escalating before four weeks at a dose.
Staying longer at a dose is allowed
If a dose is hard to tolerate, the labels support staying on it longer rather than pushing ahead — and 1.7 mg is an accepted Wegovy maintenance dose if 2.4 mg is not tolerated. The Slow and Very slow pace options model exactly this: +2 or +4 weeks at every step. Delaying escalation is generally preferable to stopping the medication, but only your prescriber can decide the right dose and timing for you.
Planning refills, travel, and missed doses
Missed-dose rules depend on the product. For Wegovy injection, an isolated missed dose depends on whether the next scheduled injection is more than 48 hours away. After two or more consecutive omissions, ask the prescriber about resuming or repeating dose escalation. Ozempic uses a five-day window, while Mounjaro and Zepbound use a four-day window. Never double a dose. Check current product instructions before changing the injection day.